SHBG (Extended): Sex- and Cycle-Related Differences Explained

What Is SHBG and Why Does the "Extended" Panel Matter?

The standard SHBG test reports only the binding globulin concentration. The extended panel adds total testosterone, albumin, and the Vermeulen-calculated free testosterone and bioavailable testosterone fractions. This matters because roughly 44 to 65% of circulating testosterone is bound tightly to SHBG and is biologically inactive. Another 30 to 54% binds loosely to albumin and remains bioavailable. Only 1 to 3% is truly free.

A 2016 analysis published in the Journal of Clinical Endocrinology and Metabolism confirmed that calculated free testosterone using the Vermeulen formula correlates well with gold-standard equilibrium dialysis when albumin is measured simultaneously ([1]).

How SHBG Binds Sex Hormones

SHBG is a homodimeric glycoprotein synthesized almost entirely in the liver. Each dimer has one high-affinity steroid-binding site. Binding affinity follows this hierarchy: DHT binds most tightly, then testosterone, then estradiol. Because SHBG competes for each steroid simultaneously, a rise in one bound ligand can displace another. Elevated estradiol does not reduce SHBG. Estradiol actually stimulates SHBG gene transcription, increasing total SHBG output from the liver ([2]).

Why a Single SHBG Number Is Not Enough

Consider two men, both with total testosterone at 450 ng/dL. One has SHBG at 18 nmol/L; his calculated free testosterone is approximately 14 ng/dL, within range. The other has SHBG at 72 nmol/L; his calculated free testosterone drops to roughly 7 ng/dL, consistent with symptomatic androgen deficiency. The extended panel catches this. The raw SHBG alone does not tell you whether the patient is androgen-replete.

Reference Ranges: What the Laboratory Reports vs. What Is Optimal

Reference ranges on laboratory reports reflect the middle 95% of a tested population. They are not the same as optimal or therapeutic targets.

Male Reference Range

Most US reference laboratories report a male adult SHBG range of approximately 16.5 to 55.9 nmol/L. The Endocrine Society's 2018 guideline on androgen deficiency in men notes that SHBG rises with age at roughly 1 to 2% per year after age 40 ([3]). A 70-year-old man with SHBG at 54 nmol/L is statistically "normal" but may have free testosterone below the range seen in healthy 25-to-40-year-old men.

For men receiving testosterone replacement therapy (TRT), the International Society for Sexual Medicine (ISSM) consensus recommends targeting SHBG in the range of approximately 20 to 40 nmol/L to maintain physiological free testosterone exposure while avoiding the supraphysiological total testosterone levels that can result from trying to overcome very high SHBG binding ([4]).

Female Reference Range and Cycle Phase Variation

Premenopausal women have a substantially wider SHBG reference range than men. LabCorp reports approximately 24.6 to 122 nmol/L for premenopausal adult females. The range is wide because SHBG fluctuates across the menstrual cycle by as much as 15 to 25% in some women.

The table below shows typical SHBG shifts across cycle phases based on population studies:

| Cycle Phase | Mean Estradiol | Typical SHBG Direction | |---|---|---| | Early follicular (days 1 to 5) | 20 to 60 pg/mL | Lower end of personal range | | Late follicular / pre-ovulatory (days 10 to 14) | 150 to 400 pg/mL | Peak or near-peak | | Luteal (days 15 to 28) | 50 to 150 pg/mL | Modest decline from peak | | Menstruation | Falling | Returns toward baseline |

Data compiled from Pugeat et al. (1996) and the Endocrine Society Clinical Practice Guideline ([3],[5]).

Postmenopausal Reference Range

After natural menopause, SHBG typically falls as estradiol declines, then stabilizes. Reference ranges of 17.3 to 125 nmol/L are reported, but the population variance is large because oral estrogen therapy in some subjects drives SHBG dramatically upward. Oral estradiol has a first-pass hepatic effect that can double or triple SHBG. Transdermal estradiol bypasses this effect and raises SHBG far less ([6]).

SHBG Across the Menstrual Cycle: Clinical Interpretation

Estradiol is the dominant driver of SHBG fluctuation in premenopausal women. As the dominant follicle matures in the late follicular phase, estradiol surges to 150 to 400 pg/mL, and SHBG rises in response.

Why Cycle Phase Timing Matters for Lab Draws

Drawing SHBG in the early follicular phase gives the lowest intra-individual reading. Drawing it at the late follicular peak gives the highest. For a woman being evaluated for androgen excess (for example, polycystic ovary syndrome), a low SHBG drawn during the luteal phase may be falsely reassuring. The Androgen Excess and PCOS Society recommends drawing androgens between days 2 and 5 of the menstrual cycle for the most reproducible baseline ([7]).

A 2010 prospective cohort study (N=259 premenopausal women) published in Human Reproduction found that SHBG concentrations in the follicular phase were 18% higher on average than paired luteal-phase samples from the same women ([8]).

Free Testosterone Interpretation in Cycling Women

Because SHBG rises pre-ovulatorily, calculated free testosterone actually dips slightly at the LH surge despite rising total testosterone in some women. This can make it look as though androgenic activity is falling at the moment of peak reproductive activity. The clinical takeaway: never interpret a single free-testosterone value in a premenopausal woman without knowing her cycle day.

SHBG in Men: Age, TRT, and Metabolic Modifiers

Age-Related SHBG Rise

Hepatic SHBG production increases with age in men. A cross-sectional study (N=3,219) from the Massachusetts Male Aging Study found that SHBG increased by approximately 1.6% per year independent of total testosterone levels ([9]). By age 70, many men have SHBG levels 40 to 60% higher than at age 30.

This matters because the Massachusetts study also found that free testosterone declined with age faster than total testosterone. Men with low free testosterone and normal total testosterone reported significantly higher rates of sexual dysfunction and fatigue. The extended panel reveals what the standard total testosterone misses.

How TRT Affects SHBG

Exogenous testosterone administration suppresses SHBG modestly. Weekly intramuscular testosterone cypionate at 100 mg typically reduces SHBG by 10 to 25% within 3 to 6 months according to observational data from TRT practice cohorts. However, the dose-response is nonlinear. Men with very high baseline SHBG (above 60 nmol/L) may need higher doses to achieve free testosterone in the mid-normal range, because the new exogenous testosterone is largely sequestered by the elevated binding protein.

The HealthRX clinical team uses the following decision framework when managing men on TRT who have high SHBG:

1. If SHBG is 55 to 70 nmol/L and free testosterone is below 9 ng/dL despite total testosterone above 500 ng/dL, evaluate for secondary drivers: thyroid disease (hyperthyroidism raises SHBG), hepatic disease, low insulin, and oral estrogen medications.
2. If no reversible cause is found, consider switching from weekly to twice-weekly dosing to minimize SHBG-binding saturation during peak troughs, or consider adding 12.5 mg oral anastrozole to reduce the estradiol-driven hepatic SHBG stimulus.
3. If SHBG is below 16 nmol/L on TRT, check for insulin resistance, obesity (BMI above 30), or excessive exogenous androgen dose. Low SHBG in this context may correlate with elevated free testosterone above the therapeutic range.

Metabolic and Pharmacological Modifiers of SHBG in Men

Multiple conditions and drugs shift SHBG independently of sex hormone status:

Conditions that raise SHBG: Hyperthyroidism, cirrhosis, HIV with wasting, anorexia nervosa, and aging.

Conditions that lower SHBG: Type 2 diabetes, hypothyroidism, obesity, non-alcoholic fatty liver disease (NAFLD), high-dose glucocorticoid use, and high androgen states such as untreated or over-treated TRT.

A meta-analysis of 13 prospective studies (N=11,290) published in Diabetes Care in 2010 found that each 1 SD decrease in SHBG was associated with a 52% increased risk of type 2 diabetes in men after adjustment for BMI ([10]). SHBG is now recognized as both a marker and a possible mediator of metabolic health, independent of its hormone-transport function.

SHBG in Women: Hormonal Contraceptives, HRT, and Androgen Excess

Oral Contraceptives and SHBG

Oral contraceptive pills (OCPs) containing ethinyl estradiol are among the most potent inducers of hepatic SHBG synthesis. Combined OCPs can raise SHBG by 2-to-4-fold compared to baseline ([11]). A 2006 study in the Journal of Sexual Medicine (N=124) found that women who had used high-ethinyl-estradiol OCPs had SHBG levels that remained elevated for up to 6 months after discontinuation compared to women who had never used them ([11]). This post-pill SHBG elevation may contribute to low free testosterone and reduced libido in the months following OCP cessation.

Progestin-only pills have a variable effect depending on the progestin's androgenic index. Androgenic progestins (levonorgestrel, norethindrone) tend to lower SHBG. Less androgenic progestins (desogestrel, norgestimate, drospirenone) have minimal effect or may mildly raise SHBG.

Transdermal vs. Oral Estrogen in Menopause Therapy

The route of estrogen administration is one of the most clinically significant variables in postmenopausal SHBG management. Oral estradiol undergoes first-pass hepatic metabolism, delivering supraphysiological estradiol concentrations to the liver, which sharply stimulates SHBG synthesis. Transdermal estradiol bypasses this route entirely.

The ESTHER study (N=881, published in Circulation 2007) compared oral vs. Transdermal estradiol for VTE risk and incidentally documented that oral estradiol raised SHBG by approximately 100% from baseline, whereas transdermal estradiol raised SHBG by less than 15% ([6]).

For postmenopausal women on combined HRT who also take testosterone replacement for hypoactive sexual desire disorder (HSDD), elevated SHBG from oral estradiol can severely blunt the free testosterone response. "Switching from oral to transdermal estradiol is often the simplest intervention to improve free testosterone bioavailability in women on combined HRT," according to the British Menopause Society 2022 guidance document on testosterone for women ([12]).

SHBG and Polycystic Ovary Syndrome (PCOS)

PCOS is the leading cause of hyperandrogenism in premenopausal women, and low SHBG is both a diagnostic clue and a pathophysiological amplifier. Low SHBG in PCOS is driven primarily by hyperinsulinemia. Insulin suppresses SHBG gene expression in hepatocytes.

The Androgen Excess and PCOS Society diagnostic criteria include clinical or biochemical hyperandrogenism; low SHBG amplifies biochemical hyperandrogenism by raising free androgen index (FAI = total testosterone / SHBG x 100). An FAI above 4.5 in women is generally considered suggestive of androgen excess ([7]).

A randomized controlled trial published in Fertility and Sterility (N=112) showed that metformin 1,500 mg/day for 6 months raised SHBG by 35% in women with PCOS and insulin resistance, reducing FAI significantly without changing total testosterone ([13]). This confirms that treating the metabolic driver, not just the androgen level, normalizes SHBG.

Optimal SHBG: Population Normals vs. Functional Targets

The concept of an "optimal" SHBG range goes beyond the statistical normal. Longevity medicine and functional endocrinology practices often cite narrower targets based on outcomes data rather than population distribution.

Evidence-Based Targets by Population

Men not on TRT: SHBG between approximately 25 to 45 nmol/L is associated with the most favorable metabolic and androgen-adequacy profile based on the Massachusetts Male Aging Study ([9]) and the European Male Aging Study (N=3,369) ([14]).

Men on TRT: Target SHBG approximately 20 to 40 nmol/L as noted above ([4]).

Premenopausal women (no hormonal therapy): Cycle-phase-aware interpretation is mandatory. An SHBG below 30 nmol/L in the early follicular phase warrants evaluation for hyperandrogenism or insulin resistance, particularly if FAI is elevated.

Postmenopausal women on transdermal HRT: SHBG should ideally remain below 100 nmol/L to allow meaningful free testosterone if testosterone therapy is also prescribed. Values above 120 nmol/L on combined oral estrogen plus testosterone supplementation suggest the oral route is blunting free testosterone delivery.

Why "In-Range" Is Not Always Adequate

The Endocrine Society's Clinical Practice Guideline on testosterone therapy in women states: "The diagnosis of androgen insufficiency cannot be made on the basis of total testosterone measurement alone; SHBG and free testosterone calculation are required." ([15]) This is especially true when SHBG is at the upper end of its reference interval.

A 62-year-old woman with SHBG at 115 nmol/L and total testosterone at 35 ng/dL has a calculated free testosterone of approximately 0.15 ng/dL, below the lower limit of the premenopausal reference range. She is statistically "normal" by both values in isolation but functionally androgen-deficient by free testosterone calculation.

How to Collect the Sample Correctly

Accurate SHBG extended panel interpretation depends on proper sample collection:

• Draw fasting or at least 4 hours post-meal. Insulin surges after eating acutely suppress SHBG in some assay contexts.
• For premenopausal women, draw between days 2 to 5 of the menstrual cycle unless evaluating luteal-phase symptoms specifically.
• Testosterone in men peaks in the early morning (07:00 to 09:00). Draw before 10:00 AM for the most reproducible total and free testosterone values alongside SHBG ([3]).
• The extended panel requires a serum separator tube (SST gold top or red top per your lab's protocol). Albumin and SHBG are stable for 24 to 48 hours refrigerated.

Interpreting SHBG Alongside the Full Endocrine Picture

SHBG does not exist in isolation. Interpreting the extended panel requires at minimum:

• Total testosterone (ng/dL or nmol/L)
• SHBG (nmol/L)
• Albumin (g/dL) for Vermeulen free T calculation
• Estradiol (pg/mL), particularly in men where estrogen excess raises SHBG
• TSH, because both hyper- and hypothyroidism shift SHBG in opposite directions
• Fasting insulin or HOMA-IR as a screen for insulin-driven low SHBG

The Endocrine Society's 2018 guideline on male hypogonadism states: "Clinicians should measure serum SHBG in men in whom total testosterone is borderline or in whom there is clinical discordance between total testosterone and symptoms." ([3]) The extended panel operationalizes this recommendation by delivering all required inputs in a single order.